
AlzeCure Pharma Investor Relations Material
Latest events

Study Update
AlzeCure Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from AlzeCure Pharma
Access all reports
AlzeCure Pharma AB is a Swedish pharmaceutical company focused on developing treatments for severe diseases related to the central nervous system, particularly Alzheimer's disease. The company operates primarily through two research platforms: NeuroRestore, aimed at restoring cognitive functions by stimulating essential brain signaling pathways, and Alzstatin, which targets reducing the production of amyloid beta, a key factor in Alzheimer's pathology. AlzeCure's drug pipeline includes ACD856, a candidate for treating Alzheimer's, depression, and traumatic brain injuries, currently in phase I clinical trials, as well as several other preclinical candidates for pain and neurodegenerative conditions. AlzeCure is headquartered in Stockholn, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
ALZCUR
Country
🇸🇪 Sweden